The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study)
The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study)
复制标题
DOI：
10.1002/jmv.26925
复制
发表时间：
2021-03-26
影响因子：
12.7
通讯作者：
Venditti, Mario
中科院分区：
文献类型：
--
作者：
Ceccarelli, Giancarlo;Alessandri, Francesco;Venditti, Mario
替考拉宁对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 具有潜在的抗病毒活性，并被建议作为治疗 2019 年冠状病毒病 (COVID-19) 患者的补充选择。在这项多中心、回顾性、观察性研究中，目的是评估替考拉宁对危重患者 COVID-19 病程的影响。回顾性分析了 55 名重症监护病房 (ICU) 住院并接受最佳可用疗法治疗的重症 COVID-19 患者。其中 34 名患者还接受替考拉宁治疗（Tei-COVID 组），而 21 名患者未接受替考拉宁治疗（对照组）。 Tei-COVID 组的院内第 30 天粗死亡率 (35.2%) 低于对照组 (42.8%)，但未达到统计学显着性 (p = .654)。 Tei-COVID 组和对照组之间在 ICU 的住院时间没有观察到统计学上的显着差异 (p = .248)。 ICU住院第14天，Tei-COVID组患者的病毒清除率为64.7%，对照组患者的病毒清除率为57.1%，无统计学差异。与对照组相比，Tei-COVID 组血清 C 反应蛋白水平显着降低，但其他生化参数没有显着降低。最后，Tei-COVID 组中 25% 的 BSI 和对照组中 70.6% 的 BSI 致病菌是革兰氏阳性菌。没有观察到与替考拉宁使用相关的副作用。尽管存在一些局限性需要进一步研究，但在本研究中，替考拉宁的使用与分析结果的显着改善无关。此前已有记载，替考拉宁对 SARS-CoV-2 的抗病毒活性在早期临床阶段可能更有效。
Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID-19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID-19 in critically ill patients. Fifty-five patients with severe COVID-19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei-COVID group), while 21 without teicoplanin (control group). Crude in-hospital Day-30 mortality was lower in Tei-COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p = .654). No statistically significant differences in length of stay in the ICU were observed between Tei-COVID group and control group (p = .248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei-COVID group and 57.1% of control group, without statistical difference. Serum C-reactive protein level was significantly reduced in Tei-COVID group compared to control group, but not other biochemical parameters. Finally, Gram-positive were the causative pathogens for 25% of BSIs in Tei-COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed. Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS-CoV-2, previously documented, is probably more effective at early clinical stages.